The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This meta-analysis challenges the popular belief that anthocyanins improve brain health, showing no cognitive benefit in clinical populations, though other polyphenol subclasses still show promise.
This meta-analysis suggests carnosine may help control blood sugar in people with prediabetes or type 2 diabetes, but the results come from a small body of early studies and the lack of effect on weight and insulin means the benefit might be specific to this clinical population and the mechanism is unclear.
This is the first indexed study testing this specific combination, so while the 5.4 mmHg drop is a solid effect for a supplement, it's too early to tell how much of that credit belongs to potassium versus the olive leaf extract, or whether the benefits would hold in a larger, more diverse group.
This is among the first systematic reviews to rank collagen highly for osteoarthritis symptoms, but because the underlying trials were small and the evidence quality was rated low, the finding is more of a signal than a settled fact.
This is high-certainty evidence that B12 supplementation corrects a lab deficiency, but it does not seem to translate into the real-world benefits many parents might hope for — and since the finding comes from a single meta-analysis, it needs to be replicated before assuming it holds across all settings.
This is one of the first pooled analyses on iron for donor deferral, and the effect is unusually large, but the moderate certainty and frequent GI side effects mean the trade-off is real — it’s not a simple win.
This is the first controlled trial to link Lactobacillus acidophilus to menopause-related quality of life, but a single small study in a specific clinical population means the result needs replication before you can reliably expect the same benefit.
This is one of the first systematic reviews to look at black cumin specifically for metabolic syndrome, so while the effect size is striking, it comes from a narrow clinical population and shouldn't be assumed for healthy people.
This large effect size suggests vitamin D could be a meaningful adjunct for fibromyalgia pain, but because the underlying studies were not blinded and the pairing has rarely been tested, the result should be treated as promising but not conclusive.
The new null result doesn't overturn the strong existing evidence that selenium alone can reduce TPO antibodies, but it shows that combining it with myo-inositol may not add benefit, and the overall picture is now more contested than a simple 'selenium works' headline suggests.
This is one of the first meta-analyses on this pairing, so the null result neither proves nor disproves a tiny benefit, but it adds weight to the growing evidence that popping extra vitamin C during pregnancy doesn't meaningfully improve key outcomes like birth weight, preterm birth, or NICU stays.
The effect is unusually large for a sleep intervention in a meta-analysis, but because every study tested lavender against nothing rather than a placebo (e.g., a sham scent), the result may partly reflect expectation and ritual, not the herb itself — moderate overall evidence from six consistent trials.
This large RCT shows NAC can drastically improve mucosal visibility during endoscopy, but the effect is specific to a single procedure setting and doesn't support broader use; the novelty means replication is needed.
This is among the first systematic reviews to test vitamin D specifically for diagnosed depression, so while the effect size is unusually strong, it needs replication before you can count on it as an add-on treatment.
This post-hoc analysis of the LOVIT trial contradicts the hope that high-dose vitamin C could reduce sepsis mortality through platelet effects, and adds to a body of evidence (1 beneficial, 4 neutral) showing no clear benefit.
This null result directly contradicts the common belief that calcium supplementation in pregnancy is a proven lifesaver — yet the evidence is too weak to say it doesn't work, so the picture remains genuinely uncertain.
This is an unusually strong and consistent signal from a large body of evidence, but because none of the underlying trials required patients and researchers to be unaware of treatment, the true effect could be smaller than it appears; skeptical readers should treat the magnitude as tentative until blinded trials confirm it.
This is a striking effect from a rigorous meta-analysis, but it emerged only in a subgroup and contradictions in the same paper (like no effect on HbA1c) mean the case for green tea in metabolic syndrome is far from settled.
That's a striking statistical signal, but with only 7 small trials and extreme inconsistency (I²=82%), the size of the real-world benefit could be much smaller — or even nonexistent — for most people.
This is the largest systematic analysis to date on olive oil and glycemic control, and its null result for blood glucose, insulin, and HbA1c contradicts the popular belief that olive oil directly lowers blood sugar — though a signal for reduced insulin resistance suggests the picture may depend on dose and is far from settled.
This suggests prior pregnancy experience may not reliably translate into better supplement adherence, but because this is among the first meta-analyses on this specific question and adjusted for many confounders, the result is notable but not definitive — more research is needed to understand why the pattern occurred.
This is an early, intriguing signal from a pooled analysis, but the finding comes from a subgroup that wasn't the main focus of the study, so it needs replication before you should act on it.
This is among the first rigorous reviews of L. reuteri for mood, but the anxiety benefit comes only from animal studies, while the human depression results were null — so it's far too early to draw conclusions for people.
This is the first solid synthesis of dietary nitrate's effects in a clinical obesity population, but with just three studies and a small effect, treat it as an early hint — not a prescription.
This small, nonrandomized trial in a specific, critically ill population found no evidence magnesium prevents death or heart-rhythm problems, and the trend actually pointed toward harm — but because the confidence interval crosses zero and the study is among the first on this question, the result raises a flag rather than settling the case.
This careful, double-blind trial contradicts the hopeful hypothesis that high-dose vitamin C could save lives in pediatric septic shock — but as one of the first studies on this specific use, it's a strong counterpoint, not a final verdict.
This is the first indexed systematic review to flag zinc as potentially effective for depression, but with only one small clinical dataset behind it, the finding is a signal to watch — not a reason to supplement yet.
This is one of the first trials to show this specific combo may ease fatigue in a clinical population of older men with low libido and mild erectile issues — but the novelty means we have no replication yet, and the result can't be generalized to healthy people or to cacao as a standalone supplement.
This large, well-measured pain reduction is promising but comes from a first-of-its-kind trial in pregnant women undergoing cesarean section, so the result needs replication before it can be assumed for other types of surgery or patients.
This null result contradicts the popular belief that beta-alanine reliably boosts strength, but the picture is contested because the same review found that divided doses over several weeks do improve performance — meaning how you take it, not just whether you take it, may decide the outcome.